<DOC>
	<DOCNO>NCT01334125</DOCNO>
	<brief_summary>The significance project investigate effect adjunctive metformin therapy child adolescent double diabetes . Double diabetes describe clinical state individual posse feature type 1 type 2 diabetes . There paucity data role adjunctive metformin therapy child adolescent double diabetes . To help fill knowledge gap , investigator propose randomize , double-blind , placebo-controlled trial metformin double diabetes . Specifically , investigator evaluate change hemoglobin A1c anthropometry patient diagnosis type 1 diabetes also feature type 2 diabetes metabolic syndrome well patient type 2 diabetes possess diabetes-associated autoantibody . This help determine safety profile , efficacy adjunctive metformin therapy subject .</brief_summary>
	<brief_title>Adjunctive Metformin Therapy Double Diabetes</brief_title>
	<detailed_description>In 12-month clinical trial , 3-month run-in period precede interventional phase study . All patient place treat-to-target insulin regimen alone run-in phase . At end 3-month run-in period , participant continue treat-to-target insulin regimen , randomize either 2 arm study : experimental arm , consist treat-to-target insulin regimen plus metformin , control arm consist treat-to-target insulin regimen plus placebo . Both physician patient blind oral agent administer patient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>A . General inclusion criterion 1 . Ten 20 year age . 2 . Pubertal ( Tanner stag 25 , examination ) . 3 . Hemoglobin A1c level &gt; 8.0 % 6 month prior enrollment . 4 . All subject must access computer . B . Specific inclusion criterion : [ Subjects could either # 1 , # 2 ] . 1 . Subjects clinical biochemical feature T2DM &gt; 6mo duration also positive T1DM antibody Clinical feature : acanthosis nigricans , BMI &gt; 85 % Biochemical : evidence insulin resistance diagnosis fast insulin &gt; 27 uIU/mL ( normal range 627 ) fast blood glucose ≥ 126 mg/dL , fast cpeptide level &gt; 7.1 ng/mL ( normal range 0.9 7.1 ) , Homeostasis model insulin resistance &gt; 3.16 2 . Patients T1DM &gt; one yr duration BMI &gt; 85 % Presentation ketoacidosis diagnosis Cpeptide &lt; 0.9 ng/mL ( normal range 0.9 7.1 ) , ( insulin &lt; 6 uIU/mL ) ( NR 627 ) diagnosis ( blood glucose ≥ 126 mg/dL ) Can antibody positive negative Increased insulin requirement ( &gt; 2 Units/kg/day ) 1 . Subjects weight alter medication , orlistat . 2 . Subjects eat disorder 3 . Subjects medication insulin metformin may affect blood glucose level . 4 . Subjects abnormal hepatic function test . 5 . Subjects nephropathy , defined case overnight albumin excretion rate &gt; 200 mcg/min use first morning urine sample collection . 6 . Subjects recurrent diabetes ketoacidosis ( 2 episode past 12 month ) , recurrent severe hypoglycemia ( 2 episode hypoglycemia alter level consciousness , require assistance treat past year ) . 7 . Pregnant , breastfeed intention become pregnant use adequate contraceptive measure . 8 . Known suspected allergy metformin . 9 . The receipt investigational drug within 6 month prior trial . 10 . Active malignant neoplasm . 11 . No access computer . 12 . Subjects currently take metformin clinical purpose eligible enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Double Diabetes</keyword>
	<keyword>Type 1 diabetes</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Obesity</keyword>
	<keyword>Acanthosis nigricans</keyword>
	<keyword>Diabetes associate autoantibody</keyword>
</DOC>